Canada markets open in 8 hours 35 minutes

Eli Lilly and Company (LLY)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
550.13-19.51 (-3.42%)
At close: 04:01PM EDT
548.70 -1.43 (-0.26%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close569.64
Bid0.00 x 900
Ask0.00 x 900
Day's Range542.50 - 568.00
52 Week Range304.88 - 601.84
Avg. Volume2,908,842
Market Cap522.236B
Beta (5Y Monthly)0.32
PE Ratio (TTM)76.62
EPS (TTM)7.18
Earnings DateNov 02, 2023
Forward Dividend & Yield4.52 (0.79%)
Ex-Dividend DateAug 14, 2023
1y Target Est569.28
  • Zacks

    Top Research Reports for Eli Lilly, Toyota Motor, Accenture & Others

    Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Toyota Motor Corporation (TM) and Accenture plc (ACN).


    Obesity treatment optimism boosts Eli Lilly, Novo Nordisk while others face downturn

    Pharmaceutical majors Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) have experienced a significant increase in their market value on Thursday, driven by the potential of their weight-loss drugs, GLP-1s, to address the global obesity epidemic. This optimism has propelled sales forecasts into the hundreds of billions. However, this same optimism has negatively impacted companies that have traditionally profited from treating obesity-related complications.


    Obesity drugs by Novo Nordisk and Eli Lilly to impact healthcare economy

    Leading pharmaceutical companies, Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY), are anticipated to see significant revenue growth from their newly developed obesity drugs, according to financial analysts' predictions. These medications, known as GLP-1 receptor agonists, are considered the safest and most effective weight-loss drugs currently available. They offer potential body weight reductions of up to 20% and could also diminish patients' risk of heart attack or stroke.